MedPath

ISHARES AXJCLIMATE US$

Ownership
-
Employees
12
Market Cap
-
Website
Introduction

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

Clinical Trials

7

Active:0
Completed:2

Trial Phases

1 Phases

Not Applicable:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Not Applicable
6 (100.0%)

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Recruiting
Conditions
Acute Kidney Injury Due to Sepsis
Acute Kidney Injury
First Posted Date
2024-07-24
Last Posted Date
2025-07-18
Lead Sponsor
SeaStar Medical
Target Recruit Count
300
Registration Number
NCT06517810
Locations
🇺🇸

Children's of Alabama, Birmingham, Alabama, United States

🇺🇸

Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States

🇺🇸

UCSF Benioff Children's, San Francisco, California, United States

and more 5 locations

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

Not Applicable
Recruiting
Conditions
Acute Kidney Injury
First Posted Date
2023-03-07
Last Posted Date
2025-07-20
Lead Sponsor
SeaStar Medical
Target Recruit Count
200
Registration Number
NCT05758077
Locations
🇺🇸

University of Alabama Birmingham Hospital, Birmingham, Alabama, United States

🇺🇸

Central Arkansas Veterans Healthcare, Little Rock, Arkansas, United States

🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 27 locations

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

Not Applicable
Withdrawn
Conditions
Continuous Renal Replacement Therapy
COVID-19
Pulmonary Edema
First Posted Date
2020-09-03
Last Posted Date
2020-12-14
Lead Sponsor
SeaStar Medical
Registration Number
NCT04537975

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

Not Applicable
Completed
Conditions
ARDS
COVID
AKI
First Posted Date
2020-05-20
Last Posted Date
2021-08-05
Lead Sponsor
SeaStar Medical
Target Recruit Count
22
Registration Number
NCT04395911
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

Not Applicable
Not yet recruiting
Conditions
Acute on Chronic Systolic Congestive Heart Failure
Cardiorenal Syndrome
First Posted Date
2019-02-11
Last Posted Date
2025-06-08
Lead Sponsor
SeaStar Medical
Target Recruit Count
20
Registration Number
NCT03836482
  • Prev
  • 1
  • 2
  • Next

News

SeaStar Medical's SCD Therapy Receives $2 Million DoD Grant for Military Burn and Sepsis Research

The AREVA Institute secured a prestigious $2 million Department of Defense grant to evaluate SeaStar Medical's Selective Cytopheretic Device therapy for treating severe burns, inhalation injury, and sepsis in warfighters.

SeaStar Medical Reaches Halfway Enrollment Milestone in Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury

SeaStar Medical has reached the halfway point in its NEUTRALIZE-AKI pivotal trial, enrolling 100 of the planned 200 adult patients with acute kidney injury requiring continuous renal replacement therapy.

UNMC Researcher to Present Groundbreaking ICU Care Bundle Implementation Study at NIH

Dr. Michele Balas from UNMC College of Nursing will present research on implementing the ABCDEF Bundle in intensive care units at the NIH Pragmatic Trials Collaboratory Grand Rounds.

SeaStar Medical Secures $6M Funding to Advance Novel Extracorporeal Inflammation Therapies

SeaStar Medical has successfully closed a $6 million registered direct offering, strengthening its financial position to advance its cell-directed extracorporeal therapy development.

FDA Approves SeaStar Medical's SCD-ADULT Feasibility Study for Cardiorenal Syndrome

The FDA has approved SeaStar Medical's IDE application for SCD-ADULT to assess safety and efficacy in reducing inflammation in adults with acute heart failure.

SeaStar Medical's Selective Cytopheretic Device Receives FDA Breakthrough Designation for ESRD Inflammation

SeaStar Medical's Selective Cytopheretic Device (SCD) has been granted Breakthrough Device designation by the FDA for treating inflammation in end-stage renal disease (ESRD).

SeaStar Medical's SCD Shows Multibillion-Dollar Market Potential Across Multiple Indications

SeaStar Medical estimates a $25 to $33 billion U.S. market for its Selective Cytopheretic Device (SCD) across five indications, pending FDA approvals.

SeaStar Medical's SCD Receives FDA Breakthrough Designation for Chronic Dialysis

SeaStar Medical's Selective Cytopheretic Device (SCD) has received its fourth FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease patients undergoing chronic hemodialysis.

SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for ESRD Treatment

SeaStar Medical's SCD device receives FDA Breakthrough Device Designation for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing hemodialysis.

SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for Chronic Dialysis

SeaStar Medical's Selective Cytopheretic Device (SCD) has received Breakthrough Device Designation from the FDA for treating chronic systemic inflammation in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.